Hongyuan Pharmaceutical: It is expected that the net profit will increase by 119.57% to 166.20% compared to 2025.

Hongyuan Pharmaceutical announced that the net profit for the year 2025 is expected to be between 113 million and 137 million yuan, a year-on-year increase of 119.57% to 166.20%. The net profit after deducting non-recurring gains and losses is expected to be between 82 million and 106 million yuan, a year-on-year increase of 782.01% to 1,040.17%. The operating performance for the year 2025 is expected to significantly increase compared to the same period last year, mainly due to the impact of the lithium hexafluorophosphate business. During the reporting period, the demand in the new energy vehicle market continued to grow and the demand in the energy storage market rapidly increased, resulting in a significant improvement in the profitability of the company's lithium hexafluorophosphate business. It is estimated that the impact of non-recurring gains and losses on the net profit attributable to the shareholders of the listed company during the reporting period is approximately 31 million yuan.